Article info
PDFOriginal research
MDM2 gene amplification as selection tool for innovative targeted approaches in PD-L1 positive or negative muscle-invasive urothelial bladder carcinoma
- Correspondence to Professor Matteo Brunelli, Department of Diagnostics and Public Health, Pathology Unit, University and Hospital Trust of Verona, 37134 Verona, Italy; matteo.brunelli{at}univr.it
Citation
MDM2 gene amplification as selection tool for innovative targeted approaches in PD-L1 positive or negative muscle-invasive urothelial bladder carcinoma
Publication history
- Received September 5, 2020
- Revised October 13, 2020
- Accepted October 15, 2020
- First published November 3, 2020.
Online issue publication
January 08, 2022
Article Versions
- Previous version (8 January 2022).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.